Human immunodeficiency virus HAART

A rabbit model of 2, 3 -dideoxycytidine neurotoxicity. Lab Invest 66(l) 63-74 Apostolski S, McAlarney T et al (1993) The gpl20 glycoprotein of human immunodeficiency virus type 1 binds to sensory ganghon neurons. Ann Neurol 34(6) 855-863 Araujo AP, Nascimento OJ et al (2000) Distal sensory polyneuropathy in a cohort of HIV-infected children over five years of age. Pediatrics 106(3) E35 Authier FJ, Gheradi RK (2003) Peripheral neuropathies in HIV-infected patients in the era of HAART. Brain Pathol 13(2) 223-228... 

Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve. 2005 32 247-260. 

Successful treatment of human immunodeficiency virus (HIV-1) infection has been achieved through successful implementation of highly active antiretroviral therapy, frequently referred to as HAART. This involves simultaneous administration of both nucleoside and nonnucleoside reverse transcriptase inhibitors and one or more protease inliibitors. The common nucleoside reverse transcriptase inhibitors are the thymidine analogs didanosine (ddl), lamivudine (3TC), and zalcitabine (ddC) and the non-thymidine analogs abacavir (Ziazen), stavudine (d4T), and zidovudine (AZT). The nonnucleoside reverse transcriptase inhibitors include delavirdine, efavirenz, and nevirapine. The protease inhibitors include indinavir, nelfinavir, ritonavir, and saquinavir. Response to therapy is monitored by quantification of HIV-RNA copies (viral load) and CD-4+ T-lymphocyte count. Successful therapy is indicated when viral load is reduced to <50 copies/mL and CD-4+ count >500 per mL. 

HAART highy active antirertoviral therapy HIV human immunodeficiency virus HSV herpes simplex virus... 

There are a growing number of reports of Leishmania-human immunodeficiency virus (HIV) coinfections across the world. Leishmania-HYV coinfection has been globally controlled in southern Europe since 1997 by highly active antiretroviral therapy (HAART), but it appears to be an increasing problem in other countries such as Ethiopia, Sudan, Brazil, or India where both infections are becoming more and more prevalent [9]. The situation is particularly alarming in southern Europe, where 50-75% of adult VL cases are HIV positive. Among the 45 million people infected by HIV worldwide, an estimated one-third lives in the zones of endemic Leishmania infections [10]. Over Leishmania-YWW coinfection cases recorded... 

---